Potency worries prompt GSK flu vaccine recall
To cap off one of the least effective seasons for flu vaccines in recent memory, vaccine producer GlaxoSmithKline announced the recall of all remaining doses of a quadrivalent, affecting roughly 1.7 million jabs. Citing potency concerns, the U.K.-based drugmaker wants back all of its FluLaval Quadrivalent Thimerosal-Free vaccines in prefilled syringes, stating that over time, the vaccines can become less effective. Read more | Subscribe to FierceVaccines
To cap off one of the least effective seasons for flu vaccines in recent memory, vaccine producer GlaxoSmithKline announced the recall of all remaining doses of a quadrivalent, affecting roughly 1.7 million jabs. Citing potency concerns, the U.K.-based drugmaker wants back all of its FluLaval Quadrivalent Thimerosal-Free vaccines in prefilled syringes, stating that over time, the vaccines can become less effective. Read more | Subscribe to FierceVaccines
No comments:
Post a Comment